BTK inhibitors

Businessman climbing steps to pluck a star from the sky
Biotech

Roche links BTK drug to low relapse rate across 96-week MS trial

The phase 2 data provide evidence of durability of fenebrutinib over 96 weeks ahead of the release of pivotal trial results.
Nick Paul Taylor May 30, 2025 5:19am
3D rendering of platelets

Sanofi BTK inhibitor for blood disease raises platelet levels

Nov 5, 2024 1:42pm
positive negative up down good bad mixed

Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies

Sep 20, 2024 7:07am
plan B fail reroute road path trail miss

Sanofi's tolebrutinib fails 2 of 3 late-stage MS trials

Sep 2, 2024 1:00am
An arrow incrementally going up stairs before pointing straight up Blue background

Sanofi nails phase 3 LUNA landing, sparking race to regulators

Apr 23, 2024 2:23am
ducks in a row line up follow leader

Novartis lines up another potential indication for BTK inhibitor

Mar 9, 2024 12:00pm